Abstract Body

Background

To prevent child-mother-to-child transmission of hepatitis B (HBV PMTCT), the World Health Organization recommends HBV screening among pregnant women, testing for HBV DNA, prophylactic antivirals, and hepatitis B birth dose vaccination to newborns. Uganda is utilizing its existing HIV platforms to integrate Hepatitis B services as part of the triple-elimination strategy. While HBV screening has improved, from 12% in 2020 to 57% in 2023, there are critical gaps in subsequent steps. Limited access and long Turn Around Time for Hepatitis B Viral load testing results is a barrier to PMTCT in Uganda. The 2024 HBV guidelines recommend the use of point-of-care HBV viral load assays as an alternative approach to centralized testing. This study aims to assess the performance and operational characteristics of Xpert® HBV Viral Load as a point-of-care assay among HBV-positive pregnant women in Uganda.

Methods

We assessed the use of the Xpert® HBV assay for HBV by comparing the accuracy of the Xpert® HBV test to the standard COBAS TaqMan, using 50 archived samples, comparing levels of agreement, sensitivity, and specificity between the two platforms. Then, we implemented the Xpert® HBV test in 10 clinics in Uganda to evaluate operational characteristics, the turnaround time from sample collection to when treatment is offered. Stata 17 was used for this data analysis.

Results

The Xpert® assay showed perfect agreement with the COBAS TaqMan, achieving a sensitivity of 100% (95% CI: 90%-100%) and a specificity of 100% (95% CI: 78.2%-100%), with a coefficient of R=0.99. Currently, 71 pregnant women have tested positive for HBV and all have received Xpert® HBV test. The median viral load results turnaround time from sample collection to results release is less than 1 hour. 20% (14/71) of women had a viral load above 200,000IU/ml and were started on Tenofovir (TDF) prophylaxis on the same day, 3% (2/71) had between 20,000 IU/ml and 200,000 IU/ml, 77% had <20,000 IU/ml including target not detected. All the women with high viremia >200,000 IU/ml are being followed for adherence to TDF prophylaxis until 12 weeks post-delivery. All babies receive HBV birth dose as part of universal vaccination.

Conclusions

Using Xpert® HBV could be a valuable tool for improving linkage to HBV prophylaxis in pregnant women. The success of this study could lead to a wider use of this test in Uganda, and optimizing HBV PMTCT service delivery.